Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

M.Y. Lee, Matthew; Brooksbank, Katriona; Wetherall, Kirsty; Mangion, Kenneth; Roditi, Giles; T. Campbell, Ross; Berry, Colin; Chong, Victor; Coyle, Liz; F. Docherty, Kieran; G. Dreisbach, John; Labinjoh, Catherine; N. Lang, Ninian; Lennie, Vera; McConnachie, Alex; Murphy, Clare; J. Petrie, Colin; Petrie, J; Speirits, Iain; Sourbron, Steven; Welsh, Paul; Woodward, Rosemary; Radjenovic, Aleksandra; B. Mark, Patrick; J.V. McMurray, John; S. Jhund, Pardeep; C. Petrie, Mark; Sattar, Naveed

doi:10.1161/circulationaha.120.052186

Public

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Published in Circulation • Nov 13, 2020

Authors:

Matthew M.Y. Lee

Katriona Brooksbank

Kirsty Wetherall

Abstract

Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain. Methods: We designed ...

Subject

Medicine

Ejection fraction

Empagliflozin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!